Markets:

Overview

News

Currencies

International

Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

28.60 +0.36 (+1.27%)

Streaming Delayed Price Updated: 1:14 PM EDT, Aug 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

ACADIA Pharmaceuticals: Q2 Earnings Insights ↗

August 08, 2022

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 08, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 ↗

August 08, 2022

Via Benzinga

8 Analysts Have This to Say About ACADIA Pharmaceuticals ↗

August 05, 2022

Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter:

Via Benzinga

FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions ↗

August 05, 2022

Via Benzinga

Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today? ↗

June 21, 2022

Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug.

Via InvestorPlace

Why Acadia Pharma Shares Are Plunging Today ↗

June 21, 2022

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗

August 05, 2022

Upgrades

Via Benzinga

Benzinga Before The Bell: Should Investors Worry About Tesla's China Sales, Gold Back In Focus, Nio Smartphone Could Soon Be A Reality Other Top Financial Stories Friday, August 5 ↗

August 05, 2022

CNBC International Airlines Prepare For Mayhem Of Summer Travel Season: Report

Via Benzinga

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

August 04, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗

July 31, 2022

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...

Via Benzinga

Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022

July 25, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗

July 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap of Monday's Biotech Catalysts - End of the Day Summary ↗

July 18, 2022

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...

Via Benzinga

Acadia Seeks FDA Approval For Genetic Neurological Disorder Candidate ↗

July 18, 2022

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome.

Via Benzinga

Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome

July 18, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Where ACADIA Pharmaceuticals Stands With Analysts ↗

July 11, 2022

Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter:

Via Benzinga

Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis ↗

June 21, 2022

HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&#

Via Benzinga

67 Biggest Movers From Yesterday ↗

June 22, 2022

Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital.

Via Benzinga

Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet ↗

June 21, 2022

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 2.5% on Tuesday.

Via Benzinga

Dow Jumps 550 Points; Convey Health Solutions Shares Spike Higher ↗

June 21, 2022

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 550 points on Tuesday.

Via Benzinga

45 Stocks Moving In Tuesday's Mid-Day Session ↗

June 21, 2022

Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,.

Via Benzinga

U.S. Markets Open Higher; Lennar Earnings Top Views ↗

June 21, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 500 points on Tuesday.

Via Benzinga

Acadia Pharmaceuticals Crashes After FDA Panel Votes Down Its Alzheimer's Psychosis Drug ↗

June 21, 2022

It's not looking good for Nuplazid in Alzheimer's disease psychosis.

Via Investor's Business Daily

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗

June 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

June 21, 2022

Goldman Sachs cut SunPower Corporation. (NASDAQ: SPWR) price target from $19 to $13. SunPower shares fell 3.1% to $17.37 in pre-market trading.

Via Benzinga

Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis

June 17, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease ↗

June 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.